Autopsy report · NCT03032042

Intestinal Microbiome Post-Azythromycin/Albendazole Treatment

“We were not able to secure IRB approval in the timeline necessary to do this study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

University of California, San Francisco

Sponsor type

University, hospital or other

Conditions

Helminth Infection

Interventions

Azithromycin; Albendazole; Delayed treatment

Participants

0

Sites

1

Countries

Ethiopia

Trials that died the same way

• Real-time 3-Dimensional Echocardiography for Assessment of Cardiac Function and Congenital Heart Disease
  “Study did not receive IRB approval.” (84% match in meaning)
• Study Comparing Intubation Via Video Laryngeal Mask Airways (VLMAs) Versus Video Laryngoscopy
  “Study never approved by the IRB. Was not initiated” (79% match in meaning)
• Retroperitoneal Ligation of Uterine Artery in Total Laparoscopic Hysterectomy for Enlarged Uterus
  “IRB did not approve this study.” (78% match in meaning)
• Safety of Topical Tranexamic Acid in Total Joint Arthroplasty in High Risk Patients
  “Study did not receive IRB approval, so did not start” (76% match in meaning)
• Light Therapy to Treat Depression in Pediatric Stem Cell Therapy Recipients
  “The study did not enroll participants and had not shown significant progress since the initial IRB approval.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.